February 28, 2006
ConjuChem cleared to initiate phase I/II diabetes study
ConjuChem cleared to initiate phase I/II diabetes study
The FDA has cleared ConjuChems phase I/II protocol for the treatment of type 2 diabetes using the companys proprietary PC-DAC:Exendin-4 compound. This allows patient dosing to begin in mid-March.
In the Dominican Republic: ‘Baseball is in our blood’
SANTO DOMINGO, Dominican Republic - While American ballplayers fret about potential injuries and padding their bank accounts, the Dominican Republic plots to steal our national pastime.
Reuters Summit-Samsung SDI sees plasma price fall
(For more news from the Reuters Global Technology, Media and Telecoms Summit, please click on: http://today.reuters.com/summit/SummitInfo.aspx?name=GlobalTechS ummit06&pid=500) (Adds production forecasts, new line, details)